CJC-1295 Clinical Trial: Single-Dose Injection Maintains Pulsatile GH for Days in Humans

A single dose of CJC-1295 (long-acting GHRH analog) maintained elevated pulsatile GH secretion for several days in healthy humans with dose-dependent duration — validating once-weekly or less frequent GH-axis restoration.

Ionescu, Madalina et al.·The Journal of clinical endocrinology and metabolism·2006·Strong Evidenceclinical-trial
RPEP-01148Clinical TrialStrong Evidence2006RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical-trial
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Single SC injection of CJC-1295 maintained elevated pulsatile GH secretion and IGF-1 for days in healthy subjects, with dose-dependent duration of action — validating once-weekly (or less) dosing for sustained GH-axis restoration in the first human clinical trial.

Key Numbers

How They Did This

clinical-trial study on cjc-1295, hormone-optimization.

Why This Research Matters

Relevant for cjc-1295, hormone-optimization.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Single SC injection of CJC-1295 maintained elevated pulsatile GH secretion and IGF-1 for days in healthy subjects, with dose-dependent duration of act
Evidence Grade:
strong evidence.
Study Age:
Published in 2006.
Original Title:
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Published In:
The Journal of clinical endocrinology and metabolism, 91(12), 4792-7 (2006)
Database ID:
RPEP-01148

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What was studied?

CJC-1295 Clinical Trial: Single-Dose Injection Maintains Pulsatile GH for Days in Humans

What was found?

A single dose of CJC-1295 (long-acting GHRH analog) maintained elevated pulsatile GH secretion for several days in healthy humans with dose-dependent duration — validating once-weekly or less frequent GH-axis restoration.

Read More on RethinkPeptides

Cite This Study

RPEP-01148·https://rethinkpeptides.com/research/RPEP-01148

APA

Ionescu, Madalina; Frohman, Lawrence A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.. The Journal of clinical endocrinology and metabolism, 91(12), 4792-7.

MLA

Ionescu, Madalina, et al. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.." The Journal of clinical endocrinology and metabolism, 2006.

RethinkPeptides

RethinkPeptides Research Database. "Pulsatile secretion of growth hormone (GH) persists during c..." RPEP-01148. Retrieved from https://rethinkpeptides.com/research/ionescu-2006-pulsatile-secretion-of-growth

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.